Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis by Chuang, M. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/103341 
 
Ming-yu (Anthony) Chuang, Mohamed A. Chinnaratha, David G. Hancock, Richard Woodman, Geoffrey 
R. Wong, Charles Cock, and Robert J.L Fraser 
Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review 
and meta-analysis 
Clinical and Translational Gastroenterology, 2015; 6(3):e82-1-e82-9 
© 2015 the American College of Gastroenterology All rights reserved 2155-384X/15. Clinical and Translational 
Gastroenterology is an openaccess journal published by Nature Publishing Group. This work is licensed under a 
Creative Commons Attribution- NonCommercial-ShareAlike 4.0 International License. The images or other third 
party material in this article are included in the article’s Creative Commons license, unless indicated otherwise 
in the credit line; if the material is not included under the Creative Commons license, users will need to obtain 
permission from the license holder to reproduce the material. To view a copy of this license, visit http:// 
creativecommons.org/licenses/by-nc-sa/4.0/ 





























Topical Steroid Therapy for the Treatment of
Eosinophilic Esophagitis (EoE): A Systematic Review
and Meta-Analysis
Ming-yu (Anthony) Chuang, MBBS1, Mohamed A. Chinnaratha, MBBS, FRACP2, David G. Hancock, PhD2,
Richard Woodman, PhD, M. Biostats, M. Med Sci, B. Sci2, Geoffrey R. Wong, MBBS1, Charles Cock, MBBS, FRACP2,3 and
Robert JL. Fraser, MBBS, FRACP, PhD2,3
OBJECTIVES: Current guidelines recommend topical steroids as first-line treatment for patients with eosinophilic esophagitis
(EoE). However, the evidence for this approach has been inconsistent in earlier reports. This meta-analysis aimed to clarify the
efficacy of topical steroid treatment in active EoE using updated evidence.
METHODS: CENTRAL, MEDLINE and EMBASE databases were searched for randomized controlled trials (RCTs) published up to
May 2014 that compared topical steroids with control treatments for active EoE. Study bias was assessed using the Cochrane
Collaboration Tool, and outcomes were pooled using random effects models. The primary outcome was the mean change in
eosinophil counts. Secondary outcomes were symptom responses and adverse events.
RESULTS: In total, seven RCTs (226 patients) were included. Topical steroids were associated with a significant reduction in
esophageal mucosal eosinophil counts compared with control therapy although substantial heterogeneity between studies was
observed (weighted mean difference (WMD) − 27.2, 95% confidence interval (CI) − 45.3 to − 9.1, I2= 56.2%). Subgroup analysis
indicated the reduction in eosinophil counts was only present in studies where a proton pump inhibitor (PPI) trial was used to
exclude other diagnoses (WMD − 46.3, 95% CI − 61.3 to − 31.4, I2= 0.0%). Subdivision of studies on the use of a PPI trial also
accounted for the majority of heterogeneity among RCTs. No clear trends in symptom resolution were observed. Eleven out of 127
patients who received topical steroids developed asymptomatic esophageal candidiasis.
CONCLUSIONS: These data provide updated high-quality evidence that support current guidelines for first-line EoE treatment with
topical steroids after an initial PPI trial to exclude non-EoE pathologies (PROSPERO ID: CRD42014008828).
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INTRODUCTION
Eosinophilic esophagitis (EoE) is characterized clinically by
eosinophil-driven inflammation and esophageal
dysfunction.1–4 Although the etiology of EoE is not fully
understood, it is considered to be an immune-mediated
condition with strong links to atopy.5,6 EoE carries a significant
burden of disease, as it requires intensive monitoring and
treatment to prevent and manage complications, such as
dysphagia, food impaction, stricture formation, and nutritional
deficiencies.2,7–9 Despite being initially considered a rare
condition, current evidence suggests a prevalence of ~ 57 per
100,000 persons with an annual health-care burden of up to
$1.4 billion in the United States.10
EoE represents a major clinical challenge due to the lack of
specific clinical signs. Esophageal mucosal eosinophilia is
characteristic of EoE, but is also frequently observed in gastro-
esophageal reflux disease (GERD) and proton pump inhibitor-
responsive esophageal eosinophilia (PPI-REE).2 In addition,
there are a number of less common conditions, such as
eosinophilic gastritis and hypereosinophilic syndrome, which
can present with esophageal eosinophilia that also require
exclusion. Current American College of Gastroenterology
(ACG) Consensus Guidelines recommend an 8-week trial with
proton pump inhibitors (PPI) to exclude PPI-responsive GERD
and PPI-REE and allow for formal diagnosis of EoE,2 followed
by topical steroids as first-line treatment.2
However, these current recommendations are based on
limited evidence and inconsistent results, asmost clinical trials
assessing topical steroid treatment in EoE have been
performed on a small number of patients using relatively
diverse methodologies.2,11–18 Although the EoE literature has
been extensively reviewed,3,18,19 a robust quantitative synth-
esis of the data has not been performed to date. Meta-analysis
aims to summarize available data and provide conclusions
that are stronger than the evidence from individual trials.
Therefore, we aimed to provide an updated systematic review
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and meta-analysis to assess the evidence base for the use of
topical steroids and PPI in the current management guidelines
for EoE. We focused solely on high-quality evidence in the
literature (i.e., randomized controlled trials (RCTs)).
METHODS
Registration. This meta-analysis was registered with PROS-
PERO (http://www.crd.york.ac.uk/PROSPERO/). PROSPERO
ID: CRD42014008828.
Inclusion and exclusion criteria. The eligibility criteria for
the study were defined a priori and included RCTs that
compared topical steroid therapy with control therapies as
induction treatment for active EoE in both adult and pediatric
populations. Studies with any of the following characteristics
were excluded: non-RCTs, RCTs comparing topical steroid
therapy with oral steroid therapy, or RCTs not assessing the
treatment of active EoE (Figure 1).
Search strategy for identification of studies. A compre-
hensive literature search with no language restrictions was
conducted to identify all published and unpublished RCTs. The
electronic reference databases searched included MEDLINE
(January 1966 to May 2014), Cochrane Upper Gastrointestinal
and Pancreatic Diseases Group Trials Register, Cochrane
Central Register of Controlled Trials (CENTRAL), and EMBASE
(1980 to May 2014). The Cochrane Highly Sensitive Search
Strategy for identifying randomized trials on MEDLINE was
used.20 Sensitivity Maximizing Version, Ovid format, was
combined with relevant MeSH terms and other search terms to
identify RCTs on MEDLINE. TheMeSH terms used in the search
were “esophagitis”, “eosinophils”, and “eosinophilia”, as well as
all lower branches under these MeSH terms. The full search
strategy is displayed in Appendix 1. This MEDLINE search
strategy was adapted to the other databases searched. Search
terms included “eosinophilic esophagitis”, “swallowed”, “rando-
mized”, “steroids”, “fluticasone”, “mometasone”, and “budeso-
nide”. In addition, reference lists from the identified publications
were analyzed to identify further relevant trials. A manual search
of textbooks, reviews, and conference proceedings (abstracts
presented at Digestive Disease Week and European Gastro-
enterology Week from 2013 to 2014) was also performed.
Study selection and data abstraction. Two reviewers (MC,
MC) screened abstracts from the literature searches. Each
study’s eligibility for the meta-analysis and systematic review
was assessed on the bais of defined inclusion and exclusion
criteria, and any uncertainty was resolved through discus-
sion. Selected full-text articles were further reviewed by the
same two reviewers. There were no discrepancies between
reviewers following full-text review. For each study, data on
the methodology, inclusion and exclusion criteria, diagnostic
criteria, interventions, outcomes, and risk of bias were
collected. Authors were contacted for any missing data.
Assessment of the risk of bias. The same two reviewers
(MC, MC) also independently critically appraised the meth-
odology of each included study using the Cochrane
Collaboration tool for determining the risk of bias20 assessing
random sequence generation, allocation concealment, blind-
ing, completeness of data, and selective reporting. Each item
was assessed as having a low, high, or unclear risk of bias.
Outcome and data analysis. The primary outcome was the
mean change in eosinophil count on biopsies following
topical steroid vs control treatments. Our secondary out-
comes were symptom resolution and adverse events from
treatment. Results were reported as weighted mean differ-
ences (WMD), which compares the mean change in
eosinophil counts following topical steroid treatment vs
the mean change in eosinophil counts following control
treatments (WMD= (post-treatment−pretreatment eosino-
phil counts)topical steroid group− (post-treatment− pretreatment
eosinophil counts)control group). The pooled WMDs are
“weighted” using the s.d. in the changes in eosinophil counts
in the topical steroid and control groups using the DerSimo-
nian and Laird method. A negative WMD indicates a greater
reduction in eosinophil counts following topical steroid
compared with control treatment, whereas a positive WMD
indicates a greater reduction following control treatment. The
s.d. of the mean difference was estimated from the pre- and
post-treatment s.d. using the method outlined in the
Cochrane Handbook.20 For each meta-analysis, a random
effects model was specified using the DerSimonian and Laird
method with the estimate of heterogeneity being taken from
the Mantel–Haenszel model. Heterogeneity of net change
estimates was assessed using Cochrane’s Q and the I2
statistics where I2=100%× (Q− df)/Q. Following the
Cochrane Handbook, I2 values were interpreted as showing
moderate (30–60%), substantial (50–90%), and considerable
(75–100%) heterogeneity.20 Results of each meta-analysis
were displayed graphically using Forest plots. The potential
for “small study effects”, including publication bias, was
Figure 1 Study selection process.
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examined by visual inspection of funnel plots, in which
the s.e. was plotted against the net change for each study. All
analyses were performed in Stata (version 12.1, StataCorp,
TX, USA) using the metan, metabias, and metafunnel
commands. A priori subgroup analyses were also conducted
according to the exclusion of PPI responders, the type of
control, and the type of topical steroid used.
RESULTS
Study selection. The initial literature search yielded 921
articles (Figure 1). Studies were excluded for being meta-
analyses or systematic reviews, for having a non-randomized
design, for assessing other intervention strategies, and for
reporting preliminary or duplicate data. In total, seven RCTs
were included.11–17
Study characteristics. The key characteristics of the
included RCTs are shown in Table 1. Two studies recruited
pediatric patients (o18 years old),13,14 three studies
recruited adult patients (418 years old),11,15,16 and two
recruited a mixed population.12,17 The criteria used to define
EoE among the included studies were highly variable with a
range of eosinophil counts from 15 to 24 eosinophils per high-
powered field, as well as different requirements for epithelial
hyperplasia or clinical symptoms (Supplementary Table 2).
Treatment regimes, including the type of topical steroid,
dosage and length of treatment, also varied greatly between
studies. All seven included studies had a low risk of selection
bias (Supplementary Table 1). Two studies had a high risk of
attrition bias.11,13
The seven trials contained a total of 260 patients. Eosinophil
count data was available for 226 patients, 127 in the topical
steroid treatment group and 99 in the control group. The
number of participants in each study ranged between 30 and
42. All studies included predominantly male participants, with
a male:female ratio of ~ 5:1.
Primary outcome
Reduction in esophageal eosinophil counts. Eosinophil
counts pre- and post-topical steroid and control treatments
were obtained for all studies as a quantitative measure of
eosinophil-driven esophageal inflammation.11–17 The results
from each study were pooled using the WMD. The WMD is
calculated as the change in eosinophil counts following steroid
treatment minus the change in eosinophil counts following
control treatment. Compared with control treatment, topical
steroid treatment was associated with a significantly greater
reduction in eosinophil counts in the esophageal mucosa
(WMD −27.2, 95% CI −45.3 to −9.1; Figure 2). “Moderate” to
“substantial” heterogeneity was observed when pooling all
studies (I2=56.2%, Q=13.69, P-heterogeneity=0.03).
This result was robust when the meta-analysis was
repeated by pooling post-treatment eosinophil counts from
topical steroid vs control treatments using a standardized
mean difference method. Although the trend was maintained,
this result was no longer significant when the two studies with
a high risk of attrition bias11,13 were excluded (WMD −19.48,
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Subgroup analyses
Exclusion of PPI responders before study. An a priori
subgroup analysis was performed on the exclusion of PPI
responders before enrollment into the trial. Two studies fully
excluded PPI responders,12,17 two studies partially excluded
PPI responders,11,13 and three studies did not exclude PPI
responders14–16 (Table 1).
Among studies that partially or fully excluded PPI respon-
ders, a significantly greater reduction in eosinophil counts was
observed with topical steroid treatment compared to control
treatment (WMD −46.3, 95% CI −61.3 to − 31.4; Figure 3).
The magnitude of effect was slightly greater among studies
that fully excluded PPI responders18,21 (WMD − 53.8, 95% CI
−83.3 to −25.3) relative to studies that partially excluded PPI
responders17,19 (WMD − 43.5, 95% CI − 61.1 to − 25.9).
Among studies that did not exclude PPI responders,20,22,23 no
significant difference in eosinophil counts was observed
between topical steroid and control treatments (WMD −5.3,
95% CI − 21.8 to 11.2; Figure 3).
These results were robust when the meta-analysis was
repeated by pooling post-treatment eosinophil counts using a
standardizedmean differencemethod andwhen excluding the
two studies with a high risk of attrition bias.11,13
A major reduction in heterogeneity was observed following
subdivision on the exclusion of PPI responders, with minimal
heterogeneity in both subgroups (I2= 0.0% and 0.0%;
Figure 3).
Type of control used (placebo vs PPI). An a priori subgroup
analysis was performed on the type of control used in each
study. Five studies used placebo treatment in the control
group11–14,17 and two studies used PPI treatment in the
control group15,16 (Table 1).
Among studies that used placebo treatment in the control
group, a significantly greater reduction in eosinophil counts
was observed with topical steroid treatment compared with
control treatment (WMD −37.2, 95% CI −56.0 to − 18.5;
Figure 4). Among studies that used PPI treatment in the
control group, no significant difference in eosinophil counts
was observed between topical steroid and PPI treatment
(WMD −5.4, 95% CI −25.2 to 14.4; Figure 4).
This result was robust in a post-hoc analysis, which
excluded the study that placed all patients in both topical
steroid- and placebo-treatment groups on PPI therapy.13 This
result was also robust when the meta-analysis was repeated
by pooling post-treatment eosinophil counts using a standar-
dizedmean differencemethod, but not when excluding the two
studies with a high risk of attrition bias.11,13
An overall reduction in heterogeneity was observed follow-
ing subdivision on control type, although the “topical steroids
vs placebo” subgroup still retained “moderate” heterogeneity
(I2= 38.3%, Q=6.48, P-heterogeneity=0.17).
Type and dosage of topical steroid used (budesonide vs
fluticasone). An a priori subgroup analysis was performed on
the type and dosage of topical steroid used. Five studies
used swallowed aerosolized fluticasone,11,12,14–16 one study
used swallowed nebulized budesonide,17 and one study used
oral viscous budesonide13 (Table 1).
Compared with placebo treatment, topical steroid treatment
was associated with a significant reduction in esophageal
eosinophil counts among studies that used budesonide (WMD
−52.0, 95% CI −76.5 to −27.4), but not among studies
that used fluticasone (WMD −18.6, 95% CI −38.9 to 1.7;
Supplementary Figure 1 online). However, when this analysis
was restricted to studies that partially or fully excluded PPI
responders,11–13,17 a significant reduction in eosinophil counts
was observed in both studies that used budesonide (WMD
−51.97, 95% CI −76.54 to −27.39) and studies that used
fluticasone (WMD−43.01, 95%CI−61.87 to−24.15; Figure 5).
These results were robust when the meta-analysis was
repeated by pooling post-treatment eosinophil counts using a
standardized mean difference method. Repeating this meta-
analysis following exclusion of the studies with a high risk of
attrition bias was not possible due to insufficient study
numbers.11,13
Of the studies using swallowed aerosolized fluticasone, two
studies used a high dose (880 μg twice daily)11,12 and three
Figure 2 Forest plot of all randomized controlled trials comparing the effect of topical steroid therapy on the reduction in eosinophil counts. A significantly negative WMD
indicates a significant reduction in eosinophil counts following topical steroid vs control treatment. WMD, weighted mean difference.
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studies used a low dose (440 μg twice daily).14–16 Among
studies that used the high dose, a significantly greater
reduction in eosinophil counts was observed with topical
steroid treatment compared with control treatment (WMD
−43.0, 95% CI −61.9 to −24.2; Supplementary Figure 2).
Among studies that used the low dose, no difference in
eosinophil counts was observed between topical steroid and
control treatments (WMD −5.3, 95% CI − 21.8 to 11.2;
Supplementary Figure 2). However, this analysis was compli-
cated by other study design characteristics as the three
studies in the low-dose group also failed to exclude PPI
responders before the trial14–16 (Figure 3).
Secondary outcomes
Symptom response. Although all of the studies provided
some measure of a “symptom response” when symptoms
before and after treatment were compared, the symptom
response scoring tools varied so widely between studies that
a meaningful meta-analysis was not possible (Supplemen-
tary Table 2). For instance, one study used a combined score
from multiple symptoms,13 two studies reported binary
changes in multiple symptoms,12,14 and four studies pre-
sented a study-specific dysphagia score.11,15–17
Two studies reported a statistically significant improvement
in dysphagia,13,17 whereas the other five studies showed no
improvement.11,12,14–16 Interestingly, the two studies that
showed the significant symptom improvement were the only
two studies where budesonide was used as the topical steroid
(Table 1).
Adverse events. Topical steroid therapy was associated with
an increased risk of esophageal candidiasis compared with
non-steroid therapies. A total of 11 cases of esophageal
candidiasis were observed in 127 patients treated with topical
Figure 4 Forest plot of all randomized controlled trials comparing the effect of topical steroid therapy on the reduction in eosinophil counts, subdivided on the type of control. A
significantly negative WMD indicates a significant reduction in eosinophil counts following topical steroid vs control treatment. WMD, weighted mean difference.
Figure 3 Forest plot of all randomized controlled trials comparing the effect of topical steroid therapy on the reduction in eosinophil counts, subdivided on the exclusion of PPI
responders. A significantly negative WMD indicates a significant reduction in eosinophil counts following topical steroid vs control treatment. WMD, weighted mean difference.
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steroids compared with none in the control groups (placebo
and PPI). The number needed to harm was nine. All cases
were asymptomatic findings that responded to antifungal
treatment. No other consistent side effects were observed.
Publication bias. Publication bias was explored using a
funnel plot (Supplementary Figure 3). The funnel plot
appeared symmetrical suggesting a lack of publication bias,
although the relatively low number of studies and the
heterogeneity in study design limits interpretation of this
analysis.
DISCUSSION
EoE is an increasingly well-recognized cause of dysphagia
with a major disease burden.1–4,10,22 The condition is thought
to be an eosinophil-driven, immune-mediated disease and
thus current treatment approaches are aimed at limiting
antigen exposure with dietary restriction and reducing
inflammation with agents such as topical steroids, systemic
steroids, or biologics.2,3 In clinical studies, eosinophil counts in
the esophageal mucosa are typically used as a quantitative
measure of esophageal inflammation and thus treatment
outcome. Importantly, eosinophil counts correlate well with
symptom responses (the end goal of treatment), but only when
optimized symptom analysis tools are used.21,23,24 This meta-
analysis showed that topical steroid treatment significantly
reduced eosinophil counts in the esophagus when compared
with control treatments in patients with active EoE after a
diagnostic trial of PPI (Figure 3).
In the meta-analysis, we also observed “moderate to
significant” heterogeneity among RCTs (Figure 2), in agree-
ment with the inconsistent results highlighted by earlier
qualitative reviews of the EoE literature.1–4,22 However,
subgroup analysis identified the exclusion of PPI responders
and the choice of control treatment as key contributors to this
heterogeneity (Figures 3 and 4). In an undifferentiated cohort
of patients presenting with symptoms of esophageal dysfunc-
tion and esophageal eosinophilia, a mixture of patients with
GERD, PPI-REE, and true EoE would be expected. Impor-
tantly, GERD and PPI-REE patients are PPI responsive and
steroid resistant, whereas EoE patients are PPI resistant and
steroid sensitive. Indeed, current ACG guidelines recommend
a failed PPI trial to diagnose true EoE and exclude the more
common PPI-sensitive diagnoses of GERD/PPI-REE. We
decided to retain studies that did not exclude PPI responders
in our meta-analysis, despite them not meeting the current
recommended guidelines for EoE, as the evidence for a PPI
trial still remains of low quality.2
In support of the importance of a PPI trial, we observed a
significant reduction in eosinophil counts following topical
steroid treatment only in studies that excluded PPI responders
(Figure 3). The heterogeneous patient mix in studies not
excluding PPI responders (GERD, PPI-REE, and EoE) would
be expected to bias the effect measures towards the null,
explaining the nonsignificant result in this subgroup.14–16 This
situation is further complicated in the two studies15,16 that
compared topical steroid with PPI therapy (Figure 4). In
addition to the inclusion of patients with other steroid-resistant
diagnoses, the topical steroid and PPI therapies were
effectively treating different subsets of patients (EoE vs
GERD/PPI-REE, respectively), thus confounding the compar-
ison (Figure 4). Importantly, both studies included a subgroup
analysis comparing the effectiveness of the two treatments in
patients subdivided on a diagnosis of GERD15 or an abnormal
pH status.16 As might be expected, topical steroid therapy was
most effective in patients without a diagnosis of GERD and in
patients with a normal pH status, further supporting the
importance of excluding PPI responders before treating EoE
with topical steroids. Taken together, this meta-analysis
provides strong evidence for the diagnostic use of a PPI trial
in EoE, as well as strong evidence for the use of topical
steroids in the treatment of true EoE.
We also observed weak evidence for a difference in efficacy
of budesonide relative to fluticasone treatment (Figure 5). A
number of factors may have potentially influenced this result,
including true differences in steroid effectiveness,25–27 con-
founding differences in study design (Table 1), or differences in
Figure 5 Forest plot of randomized controlled trials that excluded PPI responders comparing the effect of topical steroid therapy on the reduction in eosinophil counts,
subdivided on the type of steroid. A significantly negative WMD indicates a significant reduction in eosinophil counts following topical steroid vs control treatment. WMD, weighted
mean difference.
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the route of administration.28 In the trials included in this meta-
analysis, fluticasone was administered as a swallowed
aerosolized dose through an inhaler,11,12,14–16 whereas
budesonide was administered as an oral viscous solution13
or as a swallowed nebulized mixture,17 which may suggest an
effect related to the route of administration. This observation is
also consistent with a recently published RCT that showed
different efficacies for budesonide administered via different
routes.28
Although a robust association was observed between
topical steroid treatment and a reduction in eosinophil counts
in the esophagus, the data on symptom resolution was less
clear.29–31 Only two studies showed an improvement in
dysphagia or combined symptom score following
treatment.13,17 Interestingly, both studies used budesonide,
providing further evidence for an increased effectiveness of
budesonide relative to fluticasone (as discussed above).
However, the use of different symptommeasures in the studies
cannot be excluded as a factor influencing this observation.
Furthermore, symptom responses are easily confounded by
concurrent dietary/lifestyle factors, person-to-person variation,
and the relative reversibility/irreversibility of the underlying
dysfunction making interpretation of symptoms scores extre-
mely difficult. Indeed, the difficulty in assessing symptom
resolution is a major factor in the choice of the objective
reduction in eosinophil counts as the primary outcome in this
meta-analysis (and the majority of RCTs). The absence of a
widely accepted validated, objective symptom-scoring system
for EoE continues to hinder assessment of the true effects of
topical steroid treatment on symptom resolution. However, a
new symptom-based activity index specific to EoE has been
recently developed, which showed good correlation with
symptom responses and eosinophil counts in the EoE
patients.21 New RCTs utilizing this or similarly validated
symptom tools may enhance our understanding of the
relationship between eosinophilic inflammation and symptom
resolution following topical steroid treatment.
Consistent with previous reports,11–17 topical steroid treat-
ment was associated with minimal side effects overall. The
most common adverse events were asymptomatic candida
infections that resolved with antifungal treatment. This result
suggests that topical steroid treatment is not only effective but
also safe.
We identified seven RCTs in our updated meta-
analysis,11–17 three of which had not been included in a
previous systematic review.11,12,15 We were able to provide
strong, high-quality evidence for the first-line EoE treatment
with topical steroids for a number of reasons. First, we
restricted our analysis to RCTs, which provide the highest-
level evidence available. Second, the majority of the included
studies had a low risk of individual bias. Third, the strongest
reduction in eosinophil counts was observed in the subgroup
analysis pooling studies that excluded PPI responders,
consistent with current guidelines. Furthermore, this result
was robust when the two studieswith a high risk of attrition bias
were excluded from the meta-analysis.11,13 Fourth, we were
able to attribute the “moderate to significant” heterogeneity
among studies to the exclusion of PPI responders, the type of
control, and the type of steroid (Figures 3, 4, and 5), and thus
the quality of the evidence was not limited by study
heterogeneity. In addition, this reduction in heterogeneity
following a priori-defined subgroup analyses strengthens the
decision to pool the evidence from these RCTs into a single
meta-analysis. Finally, the pooled results appeared to be
precise with narrow CIs.
There are a number of limitations in this meta-analysis that
need to be considered when interpreting these results.
Although the results from this meta-analysis are highly
consistent, the outcomes are still based on a relatively small
number of RCTs with limited cohort sizes, and the results
presented here need to be interpreted in this context. Large,
multicenter RCTs that utilize the new symptom analysis tools
are still required in order to further strengthen the evidence for
topical steroid treatment in EoE. In addition, the studies
included in this systematic review varied greatly in their
definition of EoE (Table 1), which may influence the
comparisons between studies. However, the observation of
a robust positive effect despite these variable definitions could
be interpreted as further support for the use of topical steroids
in clinical practice, where EoE diagnosis will inherently vary
until international consensus on EoE definitions are available.
Finally, a meta-analysis on symptom response was not
possible due to the variability in symptom score measures
used in each study, limiting the analysis of this outcome.
CONCLUSION
In conclusion, topical steroid therapy significantly reduced
esophageal mucosal eosinophilia in EoE, but only in studies
where PPI-responsive GERD and PPI-REE patients had been
excluded. This meta-analysis provides the first high-level
evidence for the diagnostic use of a PPI trial, as well as strong
evidence for the use of topical steroids in the treatment of true
EoE, consistent with the current ACG guidelines. Although
topical steroid treatment was found to be safe and effective
in reducing eosinophil counts, its effectiveness in symptom
resolution was less clear. Further research is required to
develop a validated symptom-scoring tool.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Eosinophilic esophagitis (EoE) is an increasingly well-
recognized cause of dysphagia with a major disease
burden.
✓ Current American College of Gastroenterology (ACG)
Guidelines recommend an 8-week PPI trial, followed by
topical steroids as first-line treatment for true EoE.
✓ However, evidence for these approaches has been
inconsistent in earlier reports and robust meta-analysis has
not been performed on the updated literature.
WHAT IS NEW HERE
✓ Our meta-analysis identified seven randomized controlled
trials (RCTs), including three RCTs that had not been
previously included in a systematic review.
✓ Topical steroid therapy significantly reduced esophageal
mucosal eosinophilia in EoE, but only in studies that used a
PPI trial to exclude other diagnoses.
✓ Subdivision of RCTs on their use of a PPI trial also
accounted for the majority of heterogeneity between trials.
✓ This meta-analysis provides high-level evidence for the use
of diagnostic PPI trials and topical steroid treatment in the
management of EoE, in agreement with the ACG
guidelines.
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APPENDIX 1
Medline (OVID) search strategy
1. Randomized controlled trial.pt. (366322)
2. Controlled clinical trial.pt. (87769)
3. randomized.ab. (265828)
4. placebo.ab. (143634)




9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (3136032)
10. exp animals/ not humans.sh. (3898895)





16. exp esophagitis/ (9476) (MeSH Term [C06.405.117.620]
and lower branches)
17. r 13 or 14 or 15 or 16 (480424)
18. expeosinophils/ (19523) (MeSHTerm [A11.118.637.415.345]
and lower branches)
19. exp eosinophilia/ (19412) (MeSH Term [C15.378.553.231]
and lower branches)
20. eosinophil$.tw. (53768)
21. 18 or 19 or 20 (61912)
22. 17 and 21 (3774)
23. 11 and 22 (921)
There were no language or publication restrictions.
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